Cerebral vasoreactivity, a surrogate marker of cerebrovascular disease, is not impaired in subjects with lifetime, untre
- PDF / 477,814 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 13 Downloads / 188 Views
ORIGINAL ARTICLE
Cerebral vasoreactivity, a surrogate marker of cerebrovascular disease, is not impaired in subjects with lifetime, untreated, congenital isolated GH deficiency Cindi G. Marinho1 Hyder A. Melo2 Roberto Salvatori 3 Marco A. P. Nunes4 Carla R. P. Oliveira1 Viviane C. Campos1 Cynthia S. Barros-Oliveira1 Alécia A. Oliveira-Santos1 Nelmo V. Menezes1 Hertz T. Santos-Júnior1 Elenilde G. Santos1 Manuela A. Melo1 Joselina L. M. Oliveira5 Enaldo V. Melo1 Manuel H. Aguiar-Oliveira1 ●
●
●
●
●
●
●
●
●
●
●
●
●
●
1234567890();,:
1234567890();,:
Received: 26 May 2020 / Accepted: 4 July 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Objectives Cerebrovascular disease (CeVD) is a major cause of death and disability. The role of the GH/IGF-I axis on CeVD risk is controversial. Patients with GH deficiency (GHD) in the setting of hypopituitarism often exhibit CeVD predisposing factors, like low nitric oxide generation, endothelial dysfunction, increased visceral fat mass, increased levels of LDL cholesterol, and increased intima-media thickness, a surrogate marker of atherosclerosis. However, several confounders such as the primary hypothalamic–pituitary lesion, hormonal replacement therapies, consequences of surgery and radiotherapy, may influence this relationship. Therefore, we decided to assess cerebral vasoreactivity, a surrogate marker of CeVD, in adult subjects with untreated isolated GHD (IGHD) due to the same homozygous null mutation in the GHRH receptor gene. Methods A cross-sectional study was carried out in 25 adult IGHD subjects and 25 age- and gender-matched controls. Interview, physical examination, laboratory data, intima-media thickness measurement, and transcranial Doppler were performed. The intracranial hemodynamics (mean flow velocity, pulsatility and resistance indexes) were measured, and the response to the vasodilatory stimulus by breath-holding maneuver (breath-holding index) was calculated. Results IGHD and control groups were similar in Framingham risk score and intima-media thickness. Similarly, there was no difference in mean flow velocity, pulsatility, resistance, and breath-holding index. Conclusions Lifetime, untreated IGHD does not cause impaired cerebral vasoreactivity. Keywords GH GHRH receptor IGF-I Cerebral vasoreactivity Transcranial Doppler ●
●
●
●
Introduction * Roberto Salvatori [email protected] 1
Division of Endocrinology, Health Sciences Graduate Program, Federal University of Sergipe, Aracaju, Sergipe 49060-100, Brazil
2
Service of Transcranial Doppler, Health Sciences Graduate Program, Federal University of Sergipe, Aracaju, Sergipe 49060100, Brazil
3
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
4
Division of Angiology, Health Sciences Graduate Program, Federal University of Sergipe, Aracaju, Sergipe 49060-100, Brazil
5
Division of Cardiology, Health Sciences Graduate Program, Federal University of Sergipe, Ara
Data Loading...
